Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Update

Posted by Amy Steele on Jan 31st, 2025

Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 1,790,000 shares, a decrease of 20.8% from the December 31st total of 2,260,000 shares. Based on an average daily volume of 2,880,000 shares, the short-interest ratio is presently 0.6 days. Currently, 6.7% of the shares of the stock are sold short.

Iterum Therapeutics Price Performance

Shares of Iterum Therapeutics stock traded up $0.07 during midday trading on Thursday, hitting $1.57. 662,886 shares of the company were exchanged, compared to its average volume of 551,481. The firm has a 50 day simple moving average of $1.86 and a 200-day simple moving average of $1.43. Iterum Therapeutics has a 52 week low of $0.81 and a 52 week high of $3.02. The firm has a market cap of $43.20 million, a P/E ratio of -0.79 and a beta of 2.33.

Hedge Funds Weigh In On Iterum Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Lee Financial Co bought a new position in shares of Iterum Therapeutics in the fourth quarter valued at approximately $28,000. XTX Topco Ltd acquired a new position in Iterum Therapeutics in the third quarter worth $36,000. Finally, Apollon Financial LLC grew its holdings in shares of Iterum Therapeutics by 11.3% during the fourth quarter. Apollon Financial LLC now owns 250,250 shares of the company’s stock worth $443,000 after purchasing an additional 25,500 shares during the last quarter. 9.21% of the stock is owned by institutional investors.

About Iterum Therapeutics

(Get Free Report)

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.